Axillary hyperhidrosis Pipeline 2025: Groundbreaking Clinical Advancements by 3+ Global Leaders - DelveInsight | Featuring GlaxoSmithKline, Medytox, Theravidam, Candesant Biomedical

With Axillary hyperhidrosis reaching epidemic proportions globally and contributing significantly to comorbid conditions such as diabetes, cardiovascular disease, and certain cancers, there is a growing demand for safer, more effective treatment options. According to DelveInsight, the Axillary hyperhidrosis pipeline comprises 3+ pharmaceutical and biotech companies actively developing 3+ therapeutic candidates targeting Axillary hyperhidrosis. These therapies span various stages of clinical and non-clinical development, underscoring the intense innovation and commitment to addressing one of the most pressing public health challenges of our time.
DelveInsight's "Axillary hyperhidrosis Pipeline Insight 2025" report provides a detailed and strategic evaluation of the ongoing R&D landscape. It covers clinical trial progression, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives. The report serves as a crucial resource for stakeholders-including researchers, healthcare investors, and decision-makers, seeking insights into the evolving Axillary hyperhidrosis Therapeutics Market and the breakthroughs shaping its future trajectory.

Explore the Cutting-Edge Landscape of Axillary hyperhidrosis Drug Development @ https://www.delveinsight.com/report-store/axillary-hyperhidrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key Takeaways from the Axillary hyperhidrosis Pipeline Report

DelveInsight's Axillary hyperhidrosis pipeline report depicts a robust space with 3+ active players working to develop 3+ pipeline therapies for Axillary hyperhidrosis treatment.
In June 2024, the FDA approved Sofdra (sofpironium bromide) topical gel for the treatment of primary axillary hyperhidrosis in individuals aged 9 and older. Sofdra is an anticholinergic agent that works by selectively binding to M3 muscarinic receptors in the sweat glands to reduce sweat production. This marks the first time a new chemical entity has been approved specifically for primary axillary hyperhidrosis, offering a self-administered, once-daily topical treatment for patients who previously had limited options.
In April 2023, the FDA granted clearance for the Brella SweatControl Patch, a single-use, in-office treatment for adults with primary axillary hyperhidrosis. The patch uses Candesant Biomedical's targeted alkali thermolysis (TAT) technology, which generates localized heat through a reaction with sweat to reduce gland activity. A single 3-minute application can provide sweat reduction for up to four months.
Key Axillary hyperhidrosis companies such as GlaxoSmithKline, Medytox, Theravidam, Candesant Biomedical, and others are evaluating new drugs for Axillary hyperhidrosis to improve the treatment landscape.
Promising Axillary hyperhidrosis pipeline therapies in various stages of development include Sofpironium bromide, ET-01, DMT410, and others.

Axillary hyperhidrosis Overview:

Hyperhidrosis is a condition marked by excessive sweating, often beginning in childhood or puberty and potentially lasting a lifetime. Primary hyperhidrosis typically affects the palms, soles, underarms (axilla), groin, and under the breasts. The exact cause of axillary hyperhidrosis is unknown, but it's linked to overactive sweat gland stimulation by the nervous system. Though the sweat glands enlarge and overproduce, this is considered a secondary effect. Triggers can include anxiety, stress, pain, exercise, caffeine, or nicotine. In some cases, sweating may occur across the whole body or cause persistent facial blushing. Skin in affected areas may appear discolored, soft, cracked, or scaly. Genetic factors play a role, with up to 30% of cases having a family history. Severity can range from mild to constant, daily sweating.

Download the Axillary hyperhidrosis sample report to know in detail about the Axillary hyperhidrosis treatment market @ https://www.delveinsight.com/sample-request/axillary-hyperhidrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Axillary hyperhidrosis Pipeline Analysis
The Axillary hyperhidrosis pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Axillary hyperhidrosis Market.

Categorizes Axillary hyperhidrosis therapeutic companies by development stage: early, mid, and late-stage.

Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

Reviews emerging Axillary hyperhidrosis drugs under development based on:

Stage of development

Axillary hyperhidrosis Route of administration

Target receptor

Monotherapy vs. combination therapy

Axillary hyperhidrosis Mechanism of action

Molecular type

Offers detailed analysis of:

Company-to-company and company-academia collaborations

Axillary hyperhidrosis Licensing agreements

Funding and investment activities supporting future Axillary hyperhidrosis market advancement.

Unlock key insights into emerging Axillary hyperhidrosis therapies and market strategies here: https://www.delveinsight.com/report-store/axillary-hyperhidrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Axillary hyperhidrosis Emerging Drugs

Sofpironium bromide: Brickell Biotech Inc.
Sofpironium bromide is a newly developed compound in the U.S. being explored as a leading once-daily topical treatment for primary axillary hyperhidrosis (excessive underarm sweating). It is a retro-metabolically designed anticholinergic that targets M3 acetylcholine receptors, potentially reducing sweat production.

ET-01: Eirion Therapeutics
ET-01 is a topical botulinum treatment in development aimed at eliminating the pain, bleeding, and bruising linked to injectable botulinum products. It uses nanoemulsion-based transdermal delivery to help the large botulinum molecule absorb through the skin. ET-01 is currently in Phase 2 clinical trials for treating axillary hyperhidrosis.

DMT410: Dermata Therapeutics LLC pipeline

DMT410 is the second program utilizing the DMT400 regimen alongside botulinum toxin. Dermata Therapeutics has completed a Phase 1 proof-of-concept trial using DMT410 with BOTOX® to treat primary axillary hyperhidrosis. The treatment was well tolerated, and most participants experienced a reduction in sweating comparable to that achieved with BOTOX® injections.

Axillary hyperhidrosis Pipeline Therapeutic Assessment

Axillary hyperhidrosis Assessment by Product Type
• Mono
• Combination
• Mono/Combination

Axillary hyperhidrosis By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Axillary hyperhidrosis Assessment by Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Axillary hyperhidrosis Assessment by Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Download sample pages to get an in-depth assessment of the emerging Axillary hyperhidrosis therapies and key Axillary hyperhidrosis companies: https://www.delveinsight.com/sample-request/axillary-hyperhidrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. Axillary hyperhidrosis Current Treatment Patterns
4. Axillary hyperhidrosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Axillary hyperhidrosis Late-Stage Products (Phase-III)
7. Axillary hyperhidrosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Axillary hyperhidrosis Discontinued Products
13. Axillary hyperhidrosis Product Profiles
14. Axillary hyperhidrosis Key Companies
15. Axillary hyperhidrosis Key Products
16. Dormant and Discontinued Products
17. Axillary hyperhidrosis Unmet Needs
18. Axillary hyperhidrosis Future Perspectives
19. Axillary hyperhidrosis Analyst Review
20. Appendix
21. Report Methodology

Request the sample PDF to get detailed insights about the Axillary hyperhidrosis pipeline reports offerings: https://www.delveinsight.com/report-store/axillary-hyperhidrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.